T-Cell Therapy

Mechanism

Related News

Iovance Biotherapeutics Reports Q4 Revenue Beat, FDA Fast Track for Lung Cancer

Feb 26, 2026

Iovance Biotherapeutics reported Q4 2025 revenue of $87 million, beating estimates, while receiving FDA fast-track designation for lifileucel in non-small cell lung cancer and reporting strong sarcoma trial data.

Orca-T May Reduce Graft-Versus-Host Disease in Blood Cancer Transplant Patients

Feb 19, 2026

Orca-T, an investigational T-cell therapy under FDA priority review, is being studied to reduce graft-versus-host disease in patients undergoing allogeneic stem cell transplant for acute leukemias and high-risk blood disorders, with a decision expected in April 2026.